A-2798 becomes Alcor’s 188th patient

A-2798, a 36-year-old member with whole body cryopreservation arrangements, was declared legally deceased in December 2021 in Pennsylvania, USA. A standby was performed by Alcor’s partner, Suspended Animation (SA). SA performed a field blood substitution and transported the patient to Alcor where cryoprotective perfusion took place. A-2798 is Alcor’s 188th patient.

A-2798 becomes Alcor’s 188th patient

A-2798, a 36-year-old with whole body cryopreservation arrangements, was declared legally deceased in December 2021 in Pennsylvania, USA.

A-2999 became Alcor’s 187th patient in November 2021

A-2999, a 91-year-old male with neurocryopreservation arrangements, was declared legally dead in November 2021 in Colorado. A standby was not possible due to a rapid change in the member’s condition. A field cryoprotection was performed and then the patient was transported to Alcor. He became Alcor’s 187th patient. A full case report is being prepared.

A-1794 became Alcor’s 185th patient in September 2021

A-1794 was a 78-year-old male with neurocryopreservation arrangements. Legal death was declared in California, USA in September 2021. After transport to Alcor by Suspended Animation, cryoprotective perfusion and cryogenic cooldown took place. He became Alcor’s 185th patient. A full case report is being prepared.

A-2858 became Alcor’s 184th patient in July 2021

A-2858 was a 65-year-old female who had whole body arrangements. Legal death was declared in Minnesota, USA in July 2021 after a daily check by the hospice nurse. Due to the delay in Alcor learning of legal death, cryoprotective perfusion was not feasible. After a straight freeze by strategic partner International Cryomedicine Experts, the patient was transported to Alcor for cryogenic cooldown.

A full case report is being prepared.

A-1845 became Alcor’s 183rd patient in July 2021

A-1845 was an 83-year-old male with neuro cryopreservation arrangements. Legal death was declared in Florida, USA in July 2021. Notification was such it was only possible for one team member to arrive before pronouncement.  After an abbreviated stabilization and field neuro cryoprotection by strategic partner International Cryomedicine Experts (ICE), the patient was transported to Alcor for cryogenic cooldown.

A full case report is being prepared.

Summer 2021 Meta-Analysis Report

The second quarter 2021 issue of Cryonics includes a report on Alcor Case Metrics 2000-2020. This begins with a selection of case data for the years of 2019 and 2020 followed by a look at the 141 cases in the 21-year period from 2000 to 2020. (2000 was picked as the starting point because that year saw the introduction of vitrification technologies at Alcor.)

It’s not uncommon to find people on the internet making claims about the percentage of cases that are straight freezes, or that involve autopsies, and so on. Sometimes these lack any support and at other times the evidence is limited. The meta-analysis makes it possible to examine these numbers objectively and as accurately as possible.

For instance, in the 21 year period 2000 to 2020, 6% of cases involved an autopsy, 13 or 14% involved unattended deaths, and 23% were straight freeze. Cardiopulmonary support was provided in 66% of cases, cryoprotective perfusion was achieved in 77%, and (so far) 10% of cases have been “field cryopreservation”

See the accompanying article, “Alcor Case Metrics: Scope and Comments” by Aschwin de Wolf and Michael Benjamin for thoughts on the usefulness of the meta-analysis results. Although some factors influencing the quality of outcomes is very hard for a cryonics organization to control, none should be considered completely outside the realm of influence. This analysis helps to show where to focus our efforts. The next step in this project is to identify trends and correlation.

–Max More

Keep an eye on the Meta-Analysis Project

One Alcor-funded research project that I’m personally especially interested in is the Meta-Analysis Project. This project, led by Advanced Neural Biosciences’ Aschwin de Wolf and Michael Benjamin, gathers a vast amount of data on every one of Alcor’s cryopreservations and analyzes patterns. ANB began the Alcor Meta-Analysis Project in January 2019 with the goal of developing a quantitative method to evaluate the quality of each cryopreservation case based on a thorough review of all the available case data. The project has 3 phases.

In Phase 1, researchers review and collect relevant data points from all case reports, all raw data such as temperature data and any relevant scientific papers and, for the last decade of cases, CT scans of cryopreserved patients. In phase 2, new outcome metrics have been developed to look at variables such as cryoprotectant distribution and ice formation from the analysis of Phase 1 data. The goal of Phase 3 is to identify areas where protocol and procedure upgrades would likely have the maximum impact at improving patient preservation outcomes.

Alcor and cryonics as a whole can expect to benefit from the outcomes of this work, including:

  • a complete secure database of all the important case variables gleaned from case reports, raw data, and CT scans that can be updated with new cases.
  • important information about trends and outcomes of Alcor procedures.
  • a single or set of case metrics that provide a quantitative result that measures the quality of each patient preservation
  • information about the range of typical patient scenarios, including the modelling of unusual scenarios
  • Recommendations to improve procedures, case work, and case logistics
  • A paper to be published in a scientific journal including the exposition of the cryonics case outcome metric(s) and experimental validations

You can read the initial report in the third quarter 2020 issue of Cryonics. Next report will be published in the second quarter 2021 issue.

A-3024 became Alcor’s 182nd patient in April 2021

A-3024 was a 68-year-old male with inoperable brain cancer who had neuro cryopreservation arrangements. Legal death was declared in Northern California, USA, and the stabilization team arrived seven hours later, four hours after being notified. After stabilization and field neuro cryoprotection, the patient was transported to Alcor for cryogenic cooldown.

A full case report is being prepared.

A-2705 became Alcor’s 181st patient in August 2020

A-2705 was a 67-year-old male with neuro cryopreservation arrangements who used the death with dignity laws in his state to legally terminate his life. His cause of death was kidney failure. He was pronounced legally deceased in August in the state of Washington at 17:17 hrs on T-0 days.

A field cryoprotection (FCP) was performed before the patient was transported to Alcor. Dry ice cooldown was initiated in the field at 23:49 hrs on T-0 days. Cryogenic cooldown was initiated at Alcor at 15.05 on T+1 days and terminated on T+5 at 18.33.  The patient underwent a CT scan while remaining under liquid nitrogen. At the time of writing, A-2705 is still in a small dewar with the transfer to long-term storage yet to take place.